RT Journal Article
T1 Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial.
A1 Carmona-Bayonas, Alberto
A1 Verso, Melina
A1 Sánchez Cánovas, Manuel
A1 Rubio Pérez, Jaime
A1 García de Herreros, Marta
A1 Martínez Del Prado, Purificación
A1 Fernández Pérez, Isaura
A1 Quintanar Verduguez, Teresa
A1 Obispo Portero, Berta
A1 Pachón Olmos, Vanessa
A1 Gómez, David
A1 Ortega, Laura
A1 Serrano Moyano, Marta
A1 M Brozos, Elena
A1 Biosca, Mercedes
A1 Antonio Rebollo, Maite
A1 Teijeira Sanchez, Lucía
A1 Hernández Pérez, Carolina
A1 David Cumplido Burón, José
A1 Martínez Lago, Nieves
A1 García Pérez, Estefanía
A1 Muñoz Langa, Jose
A1 Pérez Segura, Pedro
A1 Martínez de Castro, Eva
A1 Jimenez-Fonseca, Paula
A1 Agnelli, Giancarlo
A1 Muñoz, Andrés
AB  Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis possibly being implicated.  The database is from the TESEO prospective registry that recruits cancer patients with VTE from 41 Spanish hospitals. Independent validation was conducted in a cohort from the Caravaggio trial. The objective is to evaluate the association between exposure to antiangiogenic therapies and the PE/VTE proportion in oncological patients.  In total, 1,536 subjects were evaluated; 58.4% (n = 894) had a PE and 7% (n = 108) received antiangiogenic therapy (bevacizumab in 75%). The PE/VTE proportion among antiangiogenic-treated individuals was 77/108 (71.3%) versus 817/1,428 (57.2%) among those receiving other alternative therapies (p = 0.004). The effect of the antiangiogenics on the PE/VTE proportion held up across all subgroups except for active smokers or those with chronic obstructive pulmonary disease. Exposure to antiangiogenics was associated with increased PEs, odds ratio (OR) 2.27 (95% CI, 1.42-3.63). In the Caravaggio trial, PE was present in 67% of the individuals treated with antiangiogenics, 50% of those who received chemotherapy without antiangiogenic treatment, and 60% without active therapy (p = 0.0016).  Antiangiogenics are associated with increased proportion of PE in oncological patients with VTE. If an effect on clot stability is confirmed, the concept of thrombotic risk in cancer patients should be reconsidered in qualitative terms.
YR 2022
FD 2022-04-05
LK http://hdl.handle.net/10668/19658
UL http://hdl.handle.net/10668/19658
LA en
DS RISalud
RD Apr 6, 2025